Sanofi sets no deadline for talks with Genzyme
Sanofi-Aventis does not set a limit for lead in discussions with the U.S. biotech group Genzyme, which he formalized this weekend an offer to buy, said Monday the director general of the French laboratory in Echoes.
Sanofi expressed readiness Sunday to pay $ 69 per share in cash, or a total of $ 18.5 billion (14.5 billion euros) to take control of rare diseases specialist.
Asked by the newspaper on the time he has given direction to Genzyme to meet her proposal, Chris Viehbacher said: "It's hard to say since this is a great deal for both parties. "
"The goal now is to meet to discuss," he added."We want to show our determination and seriousness, but not immediately threatening. A lot of time may elapse."
Asked about the production problems encountered by Genzyme, Chris Viehbacher said that Sanofi could help the U.S. group to solve.
"We will certainly have the opportunity to conduct due diligence," said Director General of the French laboratory. "Organic products are difficult to make but we master this technology."